Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clint T Allen

Showing results (41-50 of 102) with videos related to

Pageof 11
Sort By:
Oral Oncology|January 22, 2023
Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancerYvette Robbins, Jay Friedman, Jason Redman, et al.
Head & Neck|July 11, 2022
Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockadeKe Bai, Scott M Norberg, Cem Sievers, et al.
The Laryngoscope|September 24, 2017
The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosisJulie Ahn, Justin A Bishop, Richard B S Roden, et al.
Oncoimmunology|February 1, 2020
ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancerWenda Ye, Sreenivasulu Gunti, Clint T Allen, et al.
NPJ Vaccines|June 19, 2021
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosisMaxwell Y Lee, Simon Metenou, Douglas E Brough, et al.
Cancer Immunology Research|April 15, 2016
Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity CancersEllen C Moore, Harrison A Cash, Andria M Caruso, et al.
Cancer Immunology Research|December 6, 2018
Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and FunctionPaul E Clavijo, Jay Friedman, Yvette Robbins, et al.
Oncoimmunology|November 6, 2018
Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancerRoy Xiao, Clint T Allen, Linda Tran, et al.
Cancer Medicine|April 6, 2024
Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiationAlisha R Pershad, Punam G Thakkar, Joseph F Goodman, et al.
Oral Oncology|July 10, 2017
Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancerMegan Morisada, Ellen C Moore, Rachel Hodge, et al.
Pageof 11

Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
Oral Oncology|January 22, 2023
Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancerYvette Robbins, Jay Friedman, Jason Redman, et al.
Head & Neck|July 11, 2022
Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockadeKe Bai, Scott M Norberg, Cem Sievers, et al.
The Laryngoscope|September 24, 2017
The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosisJulie Ahn, Justin A Bishop, Richard B S Roden, et al.
Oncoimmunology|February 1, 2020
ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancerWenda Ye, Sreenivasulu Gunti, Clint T Allen, et al.
NPJ Vaccines|June 19, 2021
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosisMaxwell Y Lee, Simon Metenou, Douglas E Brough, et al.
Cancer Immunology Research|April 15, 2016
Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity CancersEllen C Moore, Harrison A Cash, Andria M Caruso, et al.
Cancer Immunology Research|December 6, 2018
Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and FunctionPaul E Clavijo, Jay Friedman, Yvette Robbins, et al.
Oncoimmunology|November 6, 2018
Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancerRoy Xiao, Clint T Allen, Linda Tran, et al.
Cancer Medicine|April 6, 2024
Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiationAlisha R Pershad, Punam G Thakkar, Joseph F Goodman, et al.
Oral Oncology|July 10, 2017
Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancerMegan Morisada, Ellen C Moore, Rachel Hodge, et al.
Pageof 11